RxDoctor Payments Data

Joseph Lambert, MD

Family Medicine · North Richland Hills, TXNPI 1114915493

Payments from drug & device makers

$616,891in general payments, 2019–2025

Across 799 payments — averaging $772.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$257K
  • Vivus LLC$140K
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$131K
  • Amgen$81K
  • AbbVie$1K
  • AstraZeneca$1K
  • plus $7K from 54 others

What the payments were for

  • Food & beverage$10,32399%
  • Education$1371%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
GSK119$256,630
Vivus LLC7$139,635
Otsuka Pharmaceutical Development & Commercialization, Inc.3$130,670
Amgen30$80,643
AbbVie(2 entities)102$1,373
AstraZeneca46$1,036
Boehringer Ingelheim58$721
Lilly USA, LLC57$662
Novo Nordisk60$635
Abbott25$477
Amarin Pharma, Inc.20$344
Pfizer33$337
Merck30$331
Astellas Pharma US Inc15$323
Takeda Pharmaceuticals U.S.A., Inc.23$260
Tris Pharma Inc12$215
Sanofi-aventis U.S. LLC11$190
Corium, LLC7$186
Antares Pharma, Inc.11$167
Dexcom, Inc.10$159
Supernus Pharmaceuticals, Inc.9$153
Daiichi Sankyo Inc.8$135
Johnson & Johnson9$116
Eisai Inc.7$113
Otsuka America Pharmaceutical, Inc.6$95
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC6$90
Novartis6$87
Idorsia Pharmaceuticals US Inc4$72
Teva Pharmaceuticals USA, Inc.5$62
Shield Therapeutics Inc1$62
Genentech USA, Inc.4$57
Biohaven Pharmaceutical Holding Company Ltd.3$55
Springworks Therapeutics, Inc.2$53
Biohaven Pharmaceuticals, Inc.3$51
Ironwood Pharmaceuticals, Inc3$42
Currax Pharmaceuticals LLC3$36
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)2$35
Althera Pharmaceuticals LLC3$34
Verity Pharmaceuticals Inc.2$30
Sunovion Pharmaceuticals Inc.2$30
Clarus Therapeutics Inc.2$30
E.r. Squibb & Sons, L.L.C.2$26
Noven Therapeutics, LLC2$26
Gilead2$26
Kowa Pharmaceuticals America, Inc.2$26
Jazz Pharmaceuticals Inc.1$26
Madrigal Pharmaceuticals1$25
Arbor Pharmaceuticals, Inc.2$25
Xeris Pharmaceuticals, Inc.1$24
Phathom Pharmaceuticals, Inc.2$23
Philips North America LLC1$22
Upsher-smith Laboratories LLC1$19
Exact Sciences1$18
Neos Therapeutics, LP1$17
Azurity Pharmaceuticals, Inc.1$17
Axsome Therapeutics, Inc.1$16
VBI Vaccine (delaware) Inc.1$16
Impel Pharmaceuticals Inc.1$16
Aytu Biopharma, Inc.1$15
Nestle Healthcare Nutrition Inc.1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$616,891 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$272,170
Medicare patients
577
Services billed
17,364

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin79$101,533
OzempicSemaglutide50$83,178
MounjaroTirzepatide69$75,795
EliquisApixaban51$61,642
JanuviaSitagliptin Phosphate21$31,206
FarxigaDapagliflozin Propanediol24$27,110
Bydureon BciseExenatide Microspheres20$18,767
ShingrixVaricella-Zoster Ge/As01b/Pf62$13,603
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog16$13,515
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$13,350
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog14$12,671
Breo ElliptaFluticasone/Vilanterol23$9,454
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog18$7,710
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/712$7,323
Spiriva RespimatTiotropium Bromide12$6,347

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Spiriva Respimat$721$107,88091 claims
Novo NordiskOzempic$635$83,17850 claims
Lilly USA, LLCMounjaro$662$75,79569 claims
PfizerEliquis, Abrysvo$337$65,14062 claims
GSKShingrix, Trelegy Ellipta, Breo Ellipta$256,630$36,40799 claims
MerckJanuvia$331$31,20621 claims
AstraZenecaFarxiga$1,036$27,11024 claims
AbbVieSynthroid$1,373$3,92636 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.

Other family medicine in North Richland Hills

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →